Windlas Biotech Past Earnings Performance
Past criteria checks 4/6
Windlas Biotech has been growing earnings at an average annual rate of 27.5%, while the Life Sciences industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 15.2% per year. Windlas Biotech's return on equity is 13%, and it has net margins of 8.8%.
Key information
27.5%
Earnings growth rate
24.9%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | 15.2% |
| Return on equity | 13.0% |
| Net Margin | 8.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Windlas Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,957 | 612 | 1,097 | 0 |
| 30 Jun 24 | 6,613 | 596 | 947 | 0 |
| 31 Mar 24 | 6,310 | 582 | 928 | 0 |
| 31 Dec 23 | 6,004 | 526 | 862 | 0 |
| 30 Sep 23 | 5,579 | 467 | 812 | 0 |
| 30 Jun 23 | 5,379 | 449 | 743 | 0 |
| 31 Mar 23 | 5,131 | 426 | 737 | 0 |
| 31 Dec 22 | 4,945 | 460 | 710 | 0 |
| 30 Sep 22 | 4,924 | 451 | 689 | 0 |
| 30 Jun 22 | 4,749 | 412 | 639 | 0 |
| 31 Mar 22 | 4,659 | 381 | 657 | 0 |
| 31 Dec 21 | 4,506 | 292 | 647 | 0 |
| 30 Sep 21 | 4,502 | 332 | 636 | 0 |
| 30 Jun 21 | 4,363 | 343 | 626 | 0 |
| 31 Mar 21 | 4,276 | 158 | 596 | 0 |
| 31 Dec 20 | 3,948 | 104 | 549 | 0 |
| 31 Mar 20 | 3,289 | 162 | 445 | 0 |
| 31 Mar 19 | 3,073 | 638 | 434 | 0 |
| 31 Mar 18 | 3,522 | 112 | 452 | 0 |
Quality Earnings: 543329 has high quality earnings.
Growing Profit Margin: 543329's current net profit margins (8.8%) are higher than last year (8.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543329's earnings have grown significantly by 27.5% per year over the past 5 years.
Accelerating Growth: 543329's earnings growth over the past year (31%) exceeds its 5-year average (27.5% per year).
Earnings vs Industry: 543329 earnings growth over the past year (31%) did not outperform the Life Sciences industry 37.9%.
Return on Equity
High ROE: 543329's Return on Equity (13%) is considered low.